📋 Korean Law Insight | Business Law & Regulatory Affairs
By Attorney NOH UJIN | HANBYOL LAW LLC, Seoul
Korean Pharmaceutical & Medical Device Regulatory Approval: A Complete Guide for Foreign Companies
South Korea is one of Asia's largest and most sophisticated pharmaceutical and medical device markets, with the sector generating over USD 20 billion in annual revenue. The nation hosts world-class clinical trial infrastructure, a universal healthcare system, and a regulatory authority — the Ministry of Food and Drug Safety (MFDS / 식품의약품안전처) — that is fully aligned with international standards including PIC/S, ICH, and ISO 13485. For foreign pharmaceutical and medical technology companies looking to enter the Korean market, understanding the regulatory approval process is not merely advisable — it is commercially essential.
This guide provides a practical, attorney-drafted overview of Korea's regulatory pathways for pharmaceuticals and medical devices, the structural requirements for foreign market entrants, post-approval obligations, and the interplay with Korea's National Health Insurance (NHI) reimbursement system.
1. The Regulatory Framework: Key Laws and Authorities
The core legislation governing pharmaceutical and medical device regulation in Korea includes:
- Pharmaceutical Affairs Act (약사법, Act No. 19200) — the foundational statute governing drug manufacturing, importation, quality control, approval, and pharmacovigilance.
- Medical Devices Act (의료기기법, Act No. 19434) — governs the classification, manufacturing, importation, quality management, and safety monitoring of medical devices.
- Act on the Safety and Support of Advanced Regenerative Medicine and Advanced Biopharmaceuticals (첨단재생의료 및 첨단바이오의약품 안전 및 지원에 관한 법률) — a 2019 statute creating a dedicated pathway for gene therapies, cell therapies, and tissue-engineered products.
- Health Insurance Act (국민건강보험법) and related HIRA/NHIS regulations governing drug and device reimbursement.
The MFDS — Korea's equivalent to the US FDA — serves as the primary licensing authority. It operates through functional divisions including the Pharmaceutical Policy Bureau, Bio-Pharmaceuticals Bureau, and Medical Devices Safety Bureau. For innovative products, applicants may engage the MFDS Regulatory Science Center for pre-submission consultations.
2. Drug Classification and Approval Categories
Under the Pharmaceutical Affairs Act and related MFDS regulations, pharmaceutical products are classified into the following approval categories:
- 신약 (New Drug — Type 1): A drug containing a new chemical entity (NCE), new biological entity (NBE), or new combination not previously approved in Korea. Full clinical trial data (Phase I–III) is required unless a waiver is granted based on foreign data. Average review timeline: 18–24 months.
- 자료제출의약품 (Data-Submitting Drug — Types 2–6): Includes drugs with new formulations, new routes of administration, new dosage forms, or new indications. The extent of clinical data depends on the sub-type.
- 바이오의약품 (Biologics): Includes vaccines, blood products, allergenics, recombinant proteins, monoclonal antibodies, and advanced therapy medicinal products (ATMPs). Subject to the Biologics Review Division of MFDS.
- 제네릭 (Generic Drugs): Require bioequivalence (BE) studies rather than clinical trials, plus demonstration of pharmaceutical equivalence (API, dosage form, strength, route).
- 바이오시밀러 (Biosimilars): Require comparative analytical, clinical, and pharmacokinetic/pharmacodynamic data against the Korean reference biologic.
| Drug Type | Data Required | Typical Timeline |
|---|
| New Chemical Entity (NCE) | Full Phase I–III clinical data | 18–24 months |
| New Indication | Phase III or abridged clinical data | 12–18 months |
| Generic Drug | BE study + pharmaceutical equivalence | 6–12 months |
| Biosimilar | Comparative analytical + PK/PD + clinical | 12–18 months |
| ATMP (Cell/Gene Therapy) | Full clinical + special safety data | 24–36 months |
3. Special Regulatory Pathways
Korea has introduced several expedited pathways modeled on FDA and EMA mechanisms:
- 희귀의약품 (Orphan Drug Designation): Available for drugs targeting diseases affecting fewer than 20,000 patients in Korea. Benefits include fee waivers, priority review, clinical trial support, and 6-year market exclusivity.
- 조건부 허가 (Conditional Approval): Allows marketing authorization for life-threatening conditions prior to completion of confirmatory clinical trials, subject to post-marketing study commitments.
- 패스트트랙 (Fast Track / Priority Review): Applicable to innovative drugs for unmet medical needs, serious conditions, or public health emergencies.
- Revolution Drugs (혁신신약 지정): A 2023 designation providing enhanced regulatory support and faster HTA evaluation for genuinely transformative medicines.
4. Medical Device Classification and Regulatory Pathway
Korea uses a four-tier classification system for medical devices:
| Class | Risk Level | Examples | Regulatory Route |
|---|
| Class I (1등급) | Lowest | Bandages, tongue depressors | Notification (신고) |
| Class II (2등급) | Low-Medium | Syringes, hearing aids | Registration with technical documents |
| Class III (3등급) | Medium-High | Infusion pumps, orthopedic implants | Full conformity review + GMP |
| Class IV (4등급) | Highest | Cardiac stents, pacemakers | Full review + clinical data + GMP inspection |
Korea recognizes GMP equivalence for manufacturers certified by the US FDA (21 CFR Part 820 / QMSR), EU Notified Bodies (MDR 2017/745), and member countries of MDSAP (Medical Device Single Audit Program). Manufacturers holding valid CE marking under EU MDR may receive an expedited review track for Classes II–IV devices.
For innovative medical devices, MFDS offers 첨단의료기기 지정 (Advanced Medical Device Designation), which provides priority review and conditional access during clinical data collection.
5. Requirements for Foreign Companies: Entity and Representation
This is a critical structural point that often surprises foreign market entrants: under the Pharmaceutical Affairs Act and Medical Devices Act, the 품목허가보유자 (marketing authorization holder / product license holder) must be a Korean resident legal entity. This means:
- Foreign pharmaceutical and device companies must either: (a) establish a Korean subsidiary (법인 설립), or (b) appoint a licensed Korean import business entity as the permit holder.
- The Korean entity is legally responsible for all regulatory submissions, GMP compliance, labeling, pharmacovigilance, and product recalls.
- Contractual arrangements between foreign originators and Korean licensees must clearly address intellectual property ownership, regulatory data rights, and liability allocation.
Many multinational companies establish a Korean subsidiary under the Foreign Investment Promotion Act (FIPA) for this purpose, benefiting from various tax incentives and foreign investment support programs offered by KOTRA's Invest KOREA.
6. GMP Compliance and Manufacturing Site Inspections
All marketed drugs and devices must comply with Korean GMP standards. The MFDS conducts:
- Domestic site inspections prior to initial product approval for most Classes III–IV devices and new biologic products.
- Overseas manufacturing site inspections (해외실사) for pharmaceuticals and biologics — the MFDS dispatches inspection teams to foreign manufacturing facilities.
- Equivalence recognition: If a site has been inspected by a PIC/S member authority within the past 2 years, Korea may accept the foreign inspection report in lieu of a MFDS inspection, subject to a document review.
Annual GMP compliance reports must be filed with the MFDS, and manufacturers must notify the MFDS of any significant manufacturing changes, product defects, or safety signals.
7. Post-Market Obligations
Approval is only the beginning of regulatory responsibility in Korea. Post-market obligations include:
- 재심사 (Re-examination): New drugs are subject to a mandatory re-examination period (4–6 years) during which the license holder must submit accumulated safety and efficacy data. Failure may result in license revocation.
- 부작용 보고 (Adverse Drug Reaction / ADR Reporting): Serious unexpected ADRs must be reported to the MFDS within 15 days; non-serious ADRs within 30 days. Periodic Safety Update Reports (PSURs) are required for most new drugs.
- PMS (Post-Market Surveillance): Medical device manufacturers must maintain a PMS system, conduct periodic performance evaluations, and file annual reports with the MFDS.
- Recall obligations (회수 및 폐기): If a product defect is identified, the license holder must initiate a recall and notify the MFDS within 5 days of becoming aware.
8. National Health Insurance Reimbursement
MFDS marketing authorization does not automatically guarantee NHI reimbursement. A separate process with the Health Insurance Review and Assessment Service (HIRA / 건강보험심사평가원) and the National Health Insurance Service (NHIS / 국민건강보험공단) is required:
- Health Technology Assessment (HTA): HIRA evaluates clinical efficacy and cost-effectiveness. For innovative drugs, the "positive list" review process applies.
- Price Negotiation: Conditional listing decisions trigger price negotiations with the NHIS Drug Price Negotiation Committee. For drugs meeting certain breakthrough criteria, risk-sharing arrangements (성과기반 계약) may be offered.
- Listed Price (상한금액) and Volume Control: Once listed, the drug price is subject to periodic reassessment, and usage growth may trigger price cuts under the Market Expansion Re-evaluation (MER) mechanism.
📌 Official References
Frequently Asked Questions (FAQ)
Q1. Can a foreign pharmaceutical company directly obtain a drug marketing authorization in Korea without establishing a Korean entity?
No. Under the Pharmaceutical Affairs Act (약사법), the marketing authorization holder (품목허가보유자) must be a Korean resident legal entity — either a Korean subsidiary of the foreign company or an independent licensed Korean import/distribution company. Foreign entities must appoint such a Korean license holder, who becomes legally responsible for all regulatory, safety, and recall obligations. However, the foreign innovator retains the option to license the product to a Korean entity contractually while retaining ownership of the underlying IP.
Q2. Does US FDA or EU EMA approval accelerate the Korean MFDS review process?
Yes, partially. While Korea does not yet have a full mutual recognition agreement (MRA) with the FDA or EMA, the MFDS does accept foreign clinical trial data generated in compliance with ICH guidelines, and may accept foreign inspection reports from PIC/S member authorities (including the FDA and EMA member states) for manufacturing site qualification. Fast Track designations from the FDA or EMA can also support a Korean Priority Review application. However, a standalone Korean regulatory dossier in the required MFDS format is still mandatory.
Q3. What is the typical timeline from Korean NDA submission to marketing authorization?
For new chemical entities (신약), the standard MFDS review timeline is approximately 18–24 months from submission of a complete application. Generic drugs (제네릭) typically receive approval in 6–12 months. Orphan drugs or products receiving Fast Track status can be processed in 10–15 months. Clinical trial authorization (IND) typically takes 30 days. The total time from entering clinical trials to commercialization in Korea is typically 5–8 years for an NCE, mirroring global development timelines.
Q4. How does Korea's medical device classification system compare to the EU MDR and US FDA systems?
Korea's four-class system (Class I–IV) broadly aligns with international frameworks. Class I/II broadly correspond to EU Class I/IIa and FDA Class I/II. Class III/IV correspond to EU Class IIb/III and FDA Class II/III requiring PMA. Notably, Korea is a member of the International Medical Device Regulators Forum (IMDRF), and the MFDS has been implementing convergence with IMDRF guidance. For EU MDR-compliant products, Korea offers a streamlined dossier review track, though a separate Korean approval (허가) is still required before marketing.
Q5. What penalties apply for marketing pharmaceuticals or medical devices without MFDS approval in Korea?
Violations are treated seriously under Korean law. Unauthorized drug marketing can result in up to 5 years imprisonment and/or fines up to KRW 50 million for individuals, and corporate fines under the Pharmaceutical Affairs Act. For medical devices, Criminal penalties under the Medical Devices Act include up to 3 years imprisonment and fines up to KRW 30 million. The MFDS also has authority to order product confiscation, business suspension, or license revocation. Critically, civil product liability claims under the Product Liability Act (제조물책임법) may also be available to injured consumers.
Q6. Can a foreign company conduct clinical trials in Korea without holding full MFDS product approval?
Yes. Korea has a robust clinical trial authorization (임상시험계획 승인, IND equivalent) system that allows foreign sponsors to conduct Phase I–III trials in Korea without a domestic marketing authorization. Korea is a globally attractive site for clinical trials due to its large patient pool, high compliance, ICHE6(R2) GCP-compliant hospitals, and competitive trial costs. Korean trial data generated under MFDS-approved IND is generally accepted by the FDA and EMA as part of a global NDA package.
Q7. How does the National Health Insurance reimbursement process work after MFDS drug approval?
MFDS approval and NHI reimbursement are separate, sequential processes. After MFDS approval, the license holder must file for NHI formulary listing with HIRA. HIRA conducts a health technology assessment (HTA) evaluating clinical benefit and cost-effectiveness against comparable treatments. If the HTA is positive (or the drug qualifies for direct listing), NHIS conducts price negotiations. The entire NHI listing process typically takes 12–24 months after MFDS approval. For ultra-rare diseases or urgent unmet needs, Korea offers an "emergency use provision" (긴급도입) for temporary NHI reimbursement prior to formal listing.
📚 Related Articles
Need Legal Assistance with Korean Regulatory Approvals?
HANBYOL LAW LLC provides expert Korean legal counsel for international pharmaceutical, biotech, and medical device companies navigating the Korean regulatory approval process, NHI reimbursement pathways, and post-market compliance obligations.
📧
ujin95@hanbl.co.kr | 🌐
www.hanbl.co.kr
Initial consultations are complimentary.
📋 韩国法律洞察 | 商业法与监管事务
作者：律师 NOH UJIN | HANBYOL LAW LLC，首尔
韩国药品及医疗器械监管审批：外国企业完整法律指南
韩国是亚洲最大且最成熟的医药和医疗器械市场之一，年行业收入超过200亿美元。负责监管审批的核心机构是食品药品安全处（MFDS / 식품의약품안전처），其监管标准与PIC/S、ICH及ISO 13485等国际标准全面对接。本指南为希望进入韩国市场的外国药企和医疗器械企业提供全面的法律实务概述。
1. 核心法律框架
- 《药事法》（약사법）：规定药品制造、进口、质量控制、许可及药物警戒的基础性法律。
- 《医疗器械法》（의료기기법）：规定医疗器械的分类、制造、进口、质量管理及安全监测。
- 《先进再生医学及先进生物药品安全与支持法》：为基因疗法、细胞疗法和组织工程产品提供专门的审批路径。
2. 药品分类与审批类别
- 新药（신약）：含有新化学实体或新生物实体的药品，须提供完整I–III期临床数据，审查周期通常为18–24个月。
- 资料提交药品（자료제출의약품）：包括新剂型、新适应症等，根据子类别不同，所需临床数据有所不同。
- 生物药品（바이오의약품）：包括疫苗、血液制品、单克隆抗体等，须向MFDS生物药品审查部门提交。
- 仿制药（제네릭）：仅需进行生物等效性（BE）研究，无需完整临床试验。
3. 医疗器械分类
| 等级 | 风险 | 代表产品 | 监管路径 |
|---|
| 一类（1등급） | 最低 | 绷带、压舌板 | 报备（신고） |
| 二类（2등급） | 低-中 | 注射器、助听器 | 注册+技术文件 |
| 三类（3등급） | 中-高 | 输液泵、骨科植入物 | 全面符合性审查+GMP |
| 四类（4등급） | 最高 | 心脏支架、起搏器 | 全面审查+临床数据+GMP检查 |
4. 外国企业的结构要求
这是外国市场进入者常常感到意外的关键结构性要求：根据《药事法》，品目许可持有人（品目許可保有者）必须是韩国居民法人实体。外国企业须在韩国设立子公司，或委任持牌韩国进口商作为许可持有人，该韩国实体将对所有监管申报、GMP合规、标签、药物警戒及产品召回负法律责任。
5. GMP合规与制造场地检查
MFDS对新生物制品和III–IV类器械进行国内场地检查，并派遣检查团队赴海外制造设施。若该场地已获PIC/S成员机构（如美国FDA）检查，MFDS可在文件审查基础上接受外方检查报告。
6. 上市后义务
- 再审查（재심사）：新药须经历4–6年强制再审查期，须提交累计安全性和有效性数据。
- 不良反应报告：严重且意外的不良反应须在15日内向MFDS报告。
- 医疗器械上市后监督（PMS）：制造商须维持PMS系统并定期提交报告。
- 召回义务：发现产品缺陷后5日内须启动召回并通知MFDS。
7. 国民健康保险报销程序
MFDS上市许可不自动赋予NHI报销资格，须通过健康保险审查评价院（HIRA）和国民健康保险公团（NHIS）的独立审查程序，包括卫生技术评估（HTA）和价格谈判，整个报销列入流程通常在MFDS批准后需额外12–24个月。
📌 官方参考资料
常见问题（FAQ）
Q1. 外国药企能否不在韩国设立法人而直接申请药品上市许可？
不能。根据《药事法》，品目许可持有人须为韩国居民法人。外国企业须设立韩国子公司或委任持牌韩国进口商作为许可持有人，方可申请上市许可。
Q2. 美国FDA或欧盟EMA的批准能加速韩国MFDS审查吗？
部分可以。MFDS接受符合ICH指南的境外临床数据，也可接受来自PIC/S成员机构的制造场地检查报告，但仍须提交符合MFDS格式的完整韩国注册文件。
Q3. 在韩国申请新药上市许可的典型时间线是多久？
新化学实体（신약）标准审查周期约18–24个月；仿制药通常为6–12个月；获得孤儿药资格或快速通道认定的产品可缩短至10–15个月。
Q4. 外国企业在韩国进行临床试验有何要求？
可以在不持有韩国上市许可的情况下开展临床试验，须获得MFDS临床试验计划批准（相当于IND）。韩国的临床试验基础设施完善，符合ICHE6(R2) GCP标准，产生的临床数据通常被FDA和EMA认可。
Q5. 未经MFDS批准擅自销售药品或医疗器械将面临何种处罚？
未经授权销售药品最高可判处5年有期徒刑及5000万韩元罚款；未经授权销售医疗器械最高可判处3年有期徒刑及3000万韩元罚款，还可能面临产品没收和经营暂停。
Q6. 如何获得NHI药品报销资格？
须在MFDS批准后向HIRA申请药品目录收录，经过HTA评估后与NHIS谈判价格。全程通常需12–24个月。急迫需求情况下，可通过"紧急引进"机制在正式列入前临时获得NHI报销。
Q7. 韩国医疗器械GMP是否承认ISO 13485认证？
是的。MFDS承认ISO 13485认证，且对参加MDSAP（医疗器械单一审计计划）的制造商，可以接受MDSAP审计报告，无需单独进行韩国GMP检查。
📚 相关文章
📋 韓国法律インサイト | ビジネス法・規制業務
著者：弁護士 NOH UJIN | HANBYOL LAW LLC、ソウル
韓国の医薬品・医療機器規制承認：外国企業向け完全法律ガイド
韓国は年間200億ドル以上の市場規模を持つアジア屈指の医薬品・医療機器市場です。主要規制機関である食品医薬品安全処（MFDS / 식품의약품안전처）は、PIC/S、ICH、ISO 13485などの国際基準に完全準拠しています。本ガイドでは、韓国の規制承認経路、外国企業の構造要件、承認後義務、国民健康保険（NHI）償還制度との関係について、弁護士の視点から実務的に解説します。
1. 規制法律フレームワーク
- 薬事法（약사법）：医薬品の製造・輸入・品質管理・承認・ファーマコビジランスを規定する基本法。
- 医療機器法（의료기기법）：医療機器の分類・製造・輸入・品質管理・安全監視を規定。
- 先端再生医療及び先端バイオ医薬品安全及び支援に関する法律：遺伝子治療・細胞治療・組織工学製品の専用承認経路を定める2019年法。
2. 医薬品分類と承認カテゴリー
| 医薬品タイプ | 必要データ | 標準審査期間 |
|---|
| 新化学実体（신약） | フルPhase I–III臨床データ | 18〜24ヶ月 |
| 新適応症 | Phase IIIまたは簡略臨床データ | 12〜18ヶ月 |
| 後発医薬品（제네릭） | 生物学的同等性試験 | 6〜12ヶ月 |
| バイオシミラー | 比較分析＋PK/PD＋臨床 | 12〜18ヶ月 |
| ATMP（細胞・遺伝子治療） | フル臨床＋特別安全性データ | 24〜36ヶ月 |
3. 医療機器分類システム
| クラス | リスク | 代表例 | 規制経路 |
|---|
| クラスI | 最低 | 包帯、舌圧子 | 届出（신고） |
| クラスII | 低〜中 | 注射器、補聴器 | 登録＋技術文書 |
| クラスIII | 中〜高 | 輸液ポンプ、整形外科インプラント | 適合性審査＋GMP |
| クラスIV | 最高 | 心臓ステント、ペースメーカー | 完全審査＋臨床データ＋GMP検査 |
4. 外国企業の構造要件
薬事法上、品目許可保有者（マーケティング認可保有者）は韓国居住の法人でなければなりません。したがって外国企業は、韓国子会社の設立またはライセンスを受けた韓国輸入業者の任命が必要です。韓国法人は、規制申請・GMP適合・表示・ファーマコビジランス・製品回収等について法的責任を負います。
5. GMP適合と製造所査察
MFDSは国内査察と海外製造所査察を実施します。PIC/S加盟機関（米FDA等）による査察済み施設については、書類審査を条件にMFDSが外国査察報告書を受け入れる場合があります。
6. 市販後義務
- 再審査（재심사）：新薬は4〜6年間の強制再審査期間中、蓄積された安全性・有効性データを提出する義務があります。
- 副作用報告：重篤かつ予期しない副作用は15日以内にMFDSへ報告。
- 医療機器PMS：製造業者はPMSシステムを維持し、定期的な報告書をMFDSに提出。
- 回収義務：製品欠陥発覚後5日以内に回収を開始し、MFDSに通知。
7. NHI償還手続き
MFDS承認後、NHI償還を受けるには健康保険審査評価院（HIRA）への収載申請および国民健康保険公団（NHIS）との価格交渉が必要です。HTA評価から価格決定まで通常12〜24ヶ月を要します。
📌 公式参考リンク
よくある質問（FAQ）
Q1. 外国企業は韓国に法人を設立せず直接承認申請できますか？
できません。薬事法上、品目許可保有者は韓国居住の法人である必要があります。韓国子会社の設立か、ライセンスを受けた韓国輸入業者の任命が必須です。
Q2. FDA/EMA承認はMFDS審査を加速しますか？
部分的には加速します。MFDS はICH準拠の外国臨床データを受け入れ、PIC/S加盟機関の製造所査察報告書を受理する場合があります。ただし、MFDSフォーマットに沿った韓国独自の申請書類は引き続き必要です。
Q3. 新薬の韓国承認にかかる標準的な期間は？
新化学実体の場合、完全な申請書提出から承認まで約18〜24ヶ月かかります。後発医薬品は6〜12ヶ月、希少疾患指定薬・ファストトラック品目は10〜15ヶ月程度です。
Q4. 韓国で未承認医薬品・医療機器を販売した場合の罰則は？
未承認医薬品の販売には最長5年の懲役・5000万ウォン以下の罰金、未承認医療機器には最長3年の懲役・3000万ウォン以下の罰金が科されます。製品没収・業務停止命令も可能です。
Q5. 製品承認なしに韓国で臨床試験を実施できますか？
はい。MFDS臨床試験計画承認（IND相当）を取得すれば、韓国での臨床試験の実施は可能です。韓国は優れた臨床試験インフラを持ち、ICH E6(R2) GCP準拠の病院でのデータはFDA・EMAにも受け入れられます。
Q6. NHI償還申請の流れは？
MFDS承認後、HIRAへの収載申請→HTA評価→NHISとの価格交渉という順序で進みます。全プロセスに12〜24ヶ月かかるのが一般的です。
Q7. 韓国のGMPはISO 13485やMDSAPを認めていますか？
はい。MFDSはISO 13485認証を認め、MDSAPメンバーの製造所についてはMDSAP監査報告書を受理することがあり、別途の韓国GMP査察が不要になる場合があります。
📚 関連記事
📋 Perspectiva Legal Coreana | Derecho Empresarial y Asuntos Regulatorios
Por el Abogado NOH UJIN | HANBYOL LAW LLC, Seúl
Aprobación Regulatoria de Medicamentos y Dispositivos Médicos en Corea: Guía Legal Completa para Empresas Extranjeras
Corea del Sur es uno de los mercados farmacéuticos y de dispositivos médicos más grandes y sofisticados de Asia, con ingresos anuales superiores a 20.000 millones de dólares. La autoridad regulatoria central es el Ministerio de Seguridad Alimentaria y Farmacéutica (MFDS), alineado con estándares internacionales como PIC/S, ICH e ISO 13485. Esta guía ofrece una visión práctica de las vías regulatorias, requisitos estructurales para empresas extranjeras, obligaciones post-aprobación y el sistema de reembolso del Seguro Nacional de Salud (NHI).
1. Marco Legal Fundamental
- Ley de Asuntos Farmacéuticos (약사법): Ley básica que regula la fabricación, importación, control de calidad, aprobación y farmacovigilancia de medicamentos.
- Ley de Dispositivos Médicos (의료기기법): Regula la clasificación, fabricación, importación, gestión de calidad y vigilancia de seguridad de dispositivos médicos.
- Ley de Medicina Regenerativa Avanzada y Biofármacos Avanzados: Crea vías de aprobación específicas para terapias génicas, celulares y productos de ingeniería tisular (2019).
2. Clasificación de Medicamentos y Categorías de Aprobación
| Tipo de Medicamento | Datos Requeridos | Plazo Estándar |
|---|
| Nueva Entidad Química (신약) | Datos clínicos completos Fase I–III | 18–24 meses |
| Nueva Indicación | Datos Fase III o abreviados | 12–18 meses |
| Medicamento Genérico | Estudio de bioequivalencia | 6–12 meses |
| Biosimilar | Comparativo analítico + PK/PD + clínico | 12–18 meses |
| ATMP (Terapia Celular/Génica) | Datos clínicos + seguridad especial | 24–36 meses |
3. Clasificación de Dispositivos Médicos
| Clase | Riesgo | Ejemplos | Vía Regulatoria |
|---|
| Clase I | Mínimo | Vendas, depresor lingual | Notificación |
| Clase II | Bajo-Medio | Jeringas, audífonos | Registro + documentos técnicos |
| Clase III | Medio-Alto | Bombas de infusión, implantes ortopédicos | Revisión de conformidad + GMP |
| Clase IV | Más alto | Stents cardíacos, marcapasos | Revisión completa + datos clínicos + inspección GMP |
4. Requisitos Estructurales para Empresas Extranjeras
Un requisito estructural crítico es que, según la Ley de Asuntos Farmacéuticos, el titular de la autorización de comercialización debe ser una persona jurídica residente en Corea. Por tanto, las empresas extranjeras deben establecer una filial coreana o designar un importador coreano con licencia como titular de la autorización. Dicha entidad coreana asume responsabilidad legal por todas las presentaciones regulatorias, cumplimiento GMP, etiquetado, farmacovigilancia y retiradas de productos.
5. Cumplimiento GMP e Inspecciones de Sitios de Fabricación
El MFDS realiza inspecciones de sitios nacionales e internacionales. Para instalaciones ya inspeccionadas por autoridades miembro de PIC/S (como la FDA de EE.UU.), el MFDS puede aceptar el informe de inspección extranjero mediante revisión documental.
6. Obligaciones Post-comercialización
- Re-examen (재심사): Los nuevos medicamentos tienen un período obligatorio de re-examen de 4–6 años durante el cual el titular debe presentar datos acumulados de seguridad y eficacia.
- Notificación de Reacciones Adversas: Las RAM graves e inesperadas deben notificarse al MFDS en 15 días.
- Vigilancia Post-comercialización de Dispositivos (PMS): Los fabricantes deben mantener un sistema PMS y presentar informes periódicos.
- Obligaciones de Retirada: Ante defectos del producto, debe iniciarse una retirada en 5 días notificando al MFDS.
7. Reembolso del Seguro Nacional de Salud (NHI)
La aprobación del MFDS no garantiza automáticamente el reembolso del NHI. Se requiere un proceso separado ante el Servicio de Revisión y Evaluación del Seguro de Salud (HIRA) y el Servicio Nacional del Seguro de Salud (NHIS), que incluye evaluación de tecnología sanitaria (HTA) y negociación de precios — todo el proceso suele tomar 12–24 meses adicionales tras la aprobación del MFDS.
📌 Referencias Oficiales
Preguntas Frecuentes (FAQ)
P1. ¿Puede una empresa farmacéutica extranjera obtener la autorización de comercialización sin establecer una entidad coreana?
No. Según la Ley de Asuntos Farmacéuticos, el titular de la autorización debe ser una persona jurídica residente en Corea. La empresa extranjera debe establecer una filial coreana o designar un importador coreano autorizado.
P2. ¿La aprobación de la FDA o EMA acelera la revisión del MFDS?
Parcialmente. El MFDS acepta datos clínicos extranjeros conformes con ICH y puede aceptar informes de inspección de fabricación de autoridades miembro de PIC/S. No obstante, sigue siendo obligatorio presentar un dossier completo en formato MFDS.
P3. ¿Cuánto tiempo tarda la aprobación de un nuevo medicamento en Corea?
Para nuevas entidades químicas, el período de revisión estándar es de 18–24 meses. Los genéricos se aprueban en 6–12 meses y los productos con designación de medicamento huérfano o vía rápida en 10–15 meses.
P4. ¿Cuáles son las sanciones por comercializar productos sin aprobación del MFDS?
La venta no autorizada de medicamentos puede conllevar hasta 5 años de prisión y multas de hasta 50 millones de KRW. Para dispositivos médicos, la pena máxima es 3 años de prisión y multas de hasta 30 millones de KRW, además de posible confiscación y suspensión de actividades.
P5. ¿Puede una empresa extranjera realizar ensayos clínicos en Corea sin aprobación de comercialización?
Sí. Es posible obtener autorización de ensayo clínico (equivalente a IND) del MFDS sin contar con autorización de comercialización en Corea. Los datos generados son generalmente aceptados por la FDA y EMA en solicitudes globales.
P6. ¿Cómo funciona el proceso de inclusión en el formulario del NHI?
Tras la aprobación del MFDS, se presenta la solicitud de inclusión ante HIRA para evaluación HTA, seguida de negociación de precios con NHIS. El proceso completo suele tomar 12–24 meses adicionales.
P7. ¿Reconoce Corea la certificación ISO 13485 para dispositivos médicos?
Sí. El MFDS reconoce la certificación ISO 13485 y, para fabricantes que participan en el MDSAP, puede aceptar informes de auditoría MDSAP sin necesidad de una inspección GMP coreana separada.
📚 Artículos Relacionados
¿Necesita Asistencia Legal?
HANBYOL LAW LLC ofrece asesoramiento jurídico experto en aprobación regulatoria farmacéutica y de dispositivos médicos, reembolso NHI y obligaciones de cumplimiento post-aprobación en Corea.
📧
ujin95@hanbl.co.kr | 🌐
www.hanbl.co.kr
Comments
Post a Comment